title: Investigating a new drug delivery nano composite membrane system based on PVA/PCL and PVA/HA(PEG) for the controlled release of biopharmaceuticals for bone infections.
abstract: The capability for sustained and gradual release of pharmaceuticals is a major requirement in the development of a guided antimicrobial bacterial control system for clinical applications. In this study, PVA gels with varying constituents that were manufactured via a refreeze/thawing route, were found to have excellent potential for antimicrobial delivery for bone infections. Cefuroxime Sodium with poly(ethylene glycol) was incorporated into 2 delivery systems poly(e-caprolactone) (PCL) and hydroxyapatite (HA), by a modified emulsion process. Our results indicate that the Cefuroxime Sodium released from poly(e-caprolactone) in PVA was tailored to a sustained release over more than 45 days, while the release from hydroxyapatite PVA reach burst maximum after 20 days. These PVA hydrogel-systems were also capable of controlled and sustained release of other biopharmaceuticals.
authors.affiliation: Nanjing University of Information and Engineering, Nanjing, Jiangsu, China; Research Institute for Flexible Materials (RIFleX), Heriot Watt University, Edinburgh, UK.
authors.forename: Taoyu
authors.initials: T
authors.lastname: Wan
authors.affiliation: Research Institute for Flexible Materials (RIFleX), Heriot Watt University, Edinburgh, UK. Electronic address: G.Stylios@hw.ac.uk.
authors.forename: George K
authors.initials: GK
authors.lastname: Stylios
authors.affiliation: Academic Department of Trauma & Orthopaedic Surgery, School of Medicine, University of Leeds, Leeds, UK.
authors.forename: Marilena
authors.initials: M
authors.lastname: Giannoudi
authors.affiliation: Academic Department of Trauma & Orthopaedic Surgery, School of Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Unit, Chapel Allerton Hospital, Leeds, UK.
authors.forename: Peter V
authors.initials: PV
authors.lastname: Giannoudis
mesh_terms: D001672:Biocompatible Materials / Q000008:administration & dosage*; D001713:Biphenyl Compounds / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000008:administration & dosage* / Q000737:chemistry; D057927:Hydrophobic and Hydrophilic Interactions; D008422:Materials Testing; D010019:Osteomyelitis / Q000188:drug therapy*; D011091:Polyesters / Q000008:administration & dosage; D011092:Polyethylene Glycols; D013696:Temperature; D054457:Tissue Scaffolds
chemical_list: D001672:Biocompatible Materials; D001713:Biphenyl Compounds; D003692:Delayed-Action Preparations; D011091:Polyesters; C502908:poly(ethylene glycol)-poly(caprolactone)-poly(ethylene glycol); D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D011092:Polyethylene Glycols
keywords: PVA hydrogels; bone infections; controlled delivery; drug delivery; nano composite; nano membrane; poly(e-caprolactone)